Tao Thi Phuong, Brandmair Katrin, Gerlach Silke, Przibilla Julia, Géniès Camille, Jacques-Jamin Carine, Schepky Andreas, Marx Uwe, Hewitt Nicola J, Maschmeyer Ilka, Kühnl Jochen
Contract development, TissUse GmbH, Berlin, Germany.
Front End Innovation, department of toxicology, Beiersdorf AG, Hamburg, Germany.
J Appl Toxicol. 2021 Oct;41(10):1553-1567. doi: 10.1002/jat.4146. Epub 2021 Feb 17.
We used TissUse's HUMIMIC Chip2 microfluidic model, incorporating reconstructed skin models and liver spheroids, to investigate the impact of consumer-relevant application scenarios on the metabolic fate of the hair dye, 4-amino-2-hydroxytoluene (AHT). After a single topical or systemic application of AHT to Chip2 models, medium was analysed for parent and metabolites over 5 days. The metabolic profile of a high dose (resulting in a circuit concentration of 100 μM based on 100% bioavailability) of AHT was the same after systemic and topical application to 96-well EpiDerm™ models. Additional experiments indicated that metabolic capacity of EpiDerm™ models were saturated at this dose. At 2.5 μM, concentrations of AHT and several of its metabolites differed between application routes. Topical application resulted in a higher C and a 327% higher area under the curve (AUC) of N-acetyl-AHT, indicating a first-pass effect in the EpiDerm™ models. In accordance with in vivo observations, there was a concomitant decrease in the C and AUC of AHT-O-sulphate after topical, compared with systemic application. A similar alteration in metabolite ratios was observed using a 24-well full-thickness skin model, EpiDermFT™, indicating that a first-pass effect was also possible to detect in a more complex model. In addition, washing the EpiDermFT™ after 30 min, thus reflecting consumer use, decreased the systemic exposure to AHT and its metabolites. In conclusion, the skin-liver Chip2 model can be used to (a) recapitulate the first-pass effect of the skin and alterations in the metabolite profile of AHT observed in vivo and (b) provide consumer-relevant data regarding leave-on/rinse-off products.
我们使用了TissUse公司的HUMIMIC Chip2微流控模型,该模型包含重建的皮肤模型和肝球体,以研究与消费者相关的应用场景对染发剂4-氨基-2-羟基甲苯(AHT)代谢命运的影响。在对Chip2模型进行单次局部或全身应用AHT后,对培养基中的母体和代谢物进行了5天的分析。在96孔EpiDerm™模型上进行全身和局部应用后,高剂量(基于100%生物利用度,导致循环浓度为100μM)AHT的代谢谱相同。额外的实验表明,EpiDerm™模型的代谢能力在该剂量下已饱和。在2.5μM时,AHT及其几种代谢物的浓度在不同应用途径之间存在差异。局部应用导致N-乙酰-AHT的C更高,曲线下面积(AUC)高327%,表明在EpiDerm™模型中存在首过效应。与体内观察结果一致,局部应用后,与全身应用相比,AHT-O-硫酸盐的C和AUC随之降低。使用24孔全层皮肤模型EpiDermFT™观察到代谢物比率有类似变化,表明在更复杂的模型中也可能检测到首过效应。此外,在30分钟后清洗EpiDermFT™,从而反映消费者的使用情况,降低了对AHT及其代谢物的全身暴露。总之,皮肤-肝脏Chip2模型可用于(a)概括皮肤的首过效应以及体内观察到的AHT代谢物谱的变化,(b)提供与消费者相关的关于留用/冲洗产品的数据。